SOURCE Phase III trial for tezepelumab in patients with severe, oral corticosteroid-dependent asthma

AstraZeneca and Amgen announced high-level results from the SOURCE Phase III trial which assessed the efficacy and safety of the potential new medicine tezepelumab compared to placebo in 150 severe asthma patients who required maintenance use of oral corticosteroids (OCS) on top of standard of care (SoC).

source https://www.pharmatutor.org/pharma-news/2020/source-phase-iii-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-dependent-asthma